Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 19.80 |
| Open | 20.09 |
| Bid | 14.60 x 1100 |
| Ask | 28.60 x 1100 |
| Day's Range | 19.29 - 20.57 |
| 52 Week Range | 16.20 - 28.95 |
| Volume | |
| Avg. Volume | 311,508 |
| Market Cap | 974.698M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.50 |
- Simply Wall St.
Strong week for Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders doesn't alleviate pain of three-year loss
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders should be happy to see the share price up 18% in the last...
- GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients Planned to Begin in 2H22 Following Our Previous Announcement of Positive Top-Line Data from Phase 1 Multiple-Ascending Dose Cohorts Strengthened Balance Sheet by Raising Gross Proceeds of $125 Million in Successful Common Stock Offering SAN DIEGO, May 12,
- GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on May 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 234,600 shares of its common stock to eight new non-executiv
